Arimidex (anastrozole) [summary of product characteristics]. HPRA.

Regulatory approval published by the Health Products Regulatory Authority.

Citation

Laboratoires Juvise Pharmaceuticals. Arimidex 1mg Film-coated Tablets (Anastrozole) [summary of product characteristics]. Health Products Regulatory Authority website. https://assets.hpra.ie/products/Human/23881/Licence_PA23154-001-001_09062021161903.pdf. Revised June 2021. Accessed May 25, 2025.

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
Treatment of hormone receptor-positive advanced breast cancer in postmenopausal women.	3
Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women.	3
Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.	3

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
HPRA (3)	ER positive	Invasive Breast Carcinoma	Anastrozole
HPRA (3)	PR positive	Invasive Breast Carcinoma	Anastrozole
HPRA (3)	ER positive, PR positive	Invasive Breast Carcinoma	Anastrozole